Test Code PENTS Pentobarbital, Serum
Reporting Name
Pentobarbital, SUseful For
Monitoring of pentobarbital therapy treatment
Performing Laboratory
Mayo Clinic Laboratories in RochesterSpecimen Type
Serum RedSpecimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube: Red top (Serum gel/SST are not acceptable)
Submission Container/Tube: Plastic vial
Specimen Volume: 2 mL
Collection Instructions:
1. Draw blood immediately before next scheduled dose.
2. Centrifuge and aliquot serum in plastic vial within 2 hours of collection.
Specimen Minimum Volume
0.7 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum Red | Refrigerated (preferred) | 14 days | |
Ambient | 14 days | ||
Frozen | 14 days |
Reference Values
Therapeutic range
Hypnotic: 1-5 mcg/mL
Therapeutic coma: 20-50 mcg/mL
Reducing intracranial pressure: 30-40 mcg/mL
This degree of sedation requires artificial respiratory support.
Toxic concentration: >10 mcg/mL
Day(s) Performed
Thursday
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
80299
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
PENTS | Pentobarbital, S | 3924-8 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
8239 | Pentobarbital, S | 3924-8 |
Clinical Information
Pentobarbital is a short-acting barbiturate with anticonvulsant and sedative-hypnotic properties. Uses include sedation induction, relief of preoperative anxiety, control of status epilepticus or seizures resulting from meningitis, tetanus, alcohol withdrawal, poisons, chorea, or eclampsia, and induction of coma in the management of cerebral ischemia and increased intracranial pressure that may follow stroke or head trauma.(1,2)
Pentobarbital is administered orally, parenterally, and rectally. The duration of hypnotic effect is about 1 to 4 hours. The drug distributes throughout the body with about 35% to 45% of a dose bound to plasma proteins in the blood. Metabolism takes place in the liver via oxidation to the inactive metabolite, hydroxypentobarbital. Elimination is biphasic; half-life is about 4 hours in the first phase, and 35 to 50 hours in the second phase. Excretion occurs through the urine, mainly as glucuronide conjugates of metabolites, with only about 1% excreted as unchanged drug.(1,2) Tolerance to the hypnotic effects of pentobarbital occurs after about 2 weeks of continuous dosing.
Interpretation
Pentobarbital concentrations above 10 mcg/mL have been associated with toxicity.
Method Description
Barbiturates are extracted from serum using solid-phase extraction techniques. The serum is buffered and eluted with organic solvent. The organic phase is dried, reconstituted, and analysis performed by gas chromatography-mass spectrometry using selected ion monitoring. The assay utilizes deuterated barbiturates as internal standards.(Unpublished Mayo method)
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | OK |
Gross icterus | OK |
Method Name
Gas Chromatography Mass Spectrometry (GC-MS)
Forms
If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.